BACTERIAL-FLORA IN MAL PERFORANT AND ANTIMICROBIAL TREATMENT WITH CEFTRIAXONE

被引:20
作者
HIRSCHL, M [1 ]
HIRSCHL, AM [1 ]
机构
[1] HYG INST,DEPT CLIN MICROBIOL,VIENNA,AUSTRIA
关键词
CEFTRIAXONE; DIABETIC FOOT; LEG ULCER;
D O I
10.1159/000239012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objectives of this pilot study were to identify the bacterial flora of neurotrophic ulcers, and to determine whether treatment with ceftriaxone improves the clinical picture. Twenty-five patients (15 male, 10 female, mean age 70 +/- 11 years) with mal perforant were treated with 2 g ceftriaxone once daily until the ulcer was healed, or for a period of 6 weeks. Biopsies were taken from the ulcer floor before and after therapy. Initially, the following bacteria were found, in order of frequency: Staphylococcus aureus, enterobacteria, coagulase-negative staphylococci, enterococci and streptococci as well as Pseudomonas aeruginosa. Under therapy with ceftriaxone, the lesions of 11 patients were healed; in 5 patients improvement > 50% was observed and in 4 patients improvement was < 50%. In 3 patients there was no change in the condition. Two patients had to stop treatment due to diarrhea. Asepsis was achieved in 5 patients despite persistence of the ulcer. The control group (25 patients without antibiotic therapy) showed the following results: healing in 6, improvement > 50% in 5, improvement < 50% in 10, and no change in 4. The results for the treatment group have to be compared with a historical control group since, for ethical reasons, the implementation of a double-blind study would not be feasible.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 11 条
[1]   THE FOOT IN DIABETES [J].
CHANTELAU, E ;
SPRAUL, M ;
SCHMID, M .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1989, 114 (26) :1034-1039
[2]   BLOOD-FLOW IN THE FOOT, POLYNEUROPATHY AND FOOT ULCERATION IN DIABETES-MELLITUS [J].
CORBIN, DOC ;
YOUNG, RJ ;
MORRISON, DC ;
HOSKINS, P ;
MCDICKEN, WN ;
HOUSLEY, E ;
CLARKE, BF .
DIABETOLOGIA, 1987, 30 (07) :468-473
[3]  
DeValentine S, 1987, Clin Podiatr Med Surg, V4, P395
[4]  
HANFLAND J, 1987, MED WELT, V38, P1405
[5]  
PARTSCH H, 1983, THERAPIEWOCHE, V33, P2252
[6]  
SAPICO FL, 1986, GERIATR MED TODAY, V5, P51
[7]  
STANDL E, 1983, MED KLIN, V78, P196
[8]  
STIEGLER H, 1988, MED KLIN, V83, P263
[9]  
STILLE W, 1983, THERAPIEWOCHE, V33, P2258
[10]  
WARD JD, 1982, DIABETOLOGIA, V22, P141